Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Dihydrolipoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | FABP3 | P05413 | 7/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrolipoic Acid SCHEMBL5827361 | 0.96 | NFKB1 (0.39) | NFKB1CA1FABP3GSTK1GPR84 | |
| Dihydrolipoic Acid SCHEMBL718014 | 0.96 | NFKB1 (0.43) | NFKB1CA1FABP3GSTK1GPR84 | |
| Dihydrolipoic Acid SCHEMBL2582100 | 0.96 | NFKB1 (0.39) | NFKB1CA1FABP3GSTK1GPR84 | |
| Dihydrolipoic Acid SCHEMBL4761909 | 0.94 | NFKB1 (0.38) | NFKB1CA1FABP3GSTK1GPR84 | |
| Dihydrolipoic Acid SCHEMBL4094129 | 0.89 | GSTK1 (0.46) | NFKB1GSTK1ENPEP | |
| Zinc Ion SCHEMBL3337795 | 0.82 | HDAC3 (0.36) | NFKB1 | |
| SCHEMBL3276879 | 0.82 | HDAC3 (0.36) | NFKB1 | |
| Tetrabuthylammonium SCHEMBL7185399 | 0.82 | NFKB1 (0.47) | NFKB1CA1FABP3GPR84BBOX1 | |
| SCHEMBL3276632 | 0.81 | HDAC3 (0.41) | — | |
| Zinc Ion SCHEMBL2580314 | 0.81 | HDAC3 (0.35) | NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100335037-C | Free-flowing powder composition comprising alpha-lipoic acid (derivatives) | DEGUSSA (DE) | 2007-09-05 | — | — | CN | claimed |
| CN-1662222-A | Free-flowing powder composition comprising alpha-lipoic acid (derivatives) | DEGUSSA (DE) | 2005-08-31 | — | — | CN | claimed |
| US-8541465-B2 | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid | SCIDOSE, LLC (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110092580-A1 | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid | SCIDOSE LLC (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092579-A1 | Solubilized formulation of docetaxel | SCIDOSE LLC (US) | 2011-04-21 | — | — | US | disclosed |
| CN-100335037-C | Free-flowing powder composition comprising alpha-lipoic acid (derivatives) | DEGUSSA (DE) | 2007-09-05 | — | — | CN | disclosed |
| CN-1662222-A | Free-flowing powder composition comprising alpha-lipoic acid (derivatives) | DEGUSSA (DE) | 2005-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092580-A1 | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid | DLST, TTPA, LIPA | NFKB1 413/4885CA1 3748/4885FABP3 818/4885 |
| US-20110092579-A1 | Solubilized formulation of docetaxel | DSG1, TTPA, TPSG1 | NFKB1 940/4885CA1 3192/4885FABP3 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.